Redefine X-linked hypophosphatemia (XLH) treatment with a targeted therapy
CRYSVITA® (burosumab-twza) is the only FDA-approved therapy targeting the underlying cause of XLH in adults and children 6 months of age and older.1
CRYSVITA efficacy and safety have been studied in children and adults with XLH.
Discover CRYSVITA’s clinical study data in children and adults.
